Overcoming Gaucher Disease: Vilol’s Path to Recovery with ERT
In this video, Vilol shares his experience with Gaucher's disease, a Lysosomal Storage Disorder. Diagnosed with Type 1 Gaucher disease at the age of 3, Vilol faced severe symptoms, including stomach and spleen enlargement, bone pain, vomiting, and nosebleeds. At a time when no treatment was available, he learned about Enzyme Replacement Therapy (ERT) and reached out to Sanofi Genzyme, who helped him access the treatment. After the first infusion of ERT, Vilol saw significant improvements in his health. With continued treatment, his swelling reduced, and he was able to live a normal life, crediting Sanofi Genzyme for his recovery.
NA
leave-site-modal-text
You are now being redirected to a third-party website.
Sanofi does not endorse or approve the content, products, services or opinions on the third-party website. Sanofi shall not be responsible or in any way liable for any injury or damage to any persons in view of any reliance placed on or action taken basis of the information on the third party website or any errors, omissions or inaccuracies and/or incompleteness of the information on the third party website.
Right answer: Both A and B. As per Diabetic & Ramadan guidelines, T2DM patients can safely continue glargine U-100 once daily at a reduced dose of 15 - 30% at Iftar1,2. Insulin glargine U-100 is safe to be used during Ramadan with no significant increase in hypoglycaemia3. One-on-one dietary educational session can also reduce the number of adverse events of fasting1.
